26
Participants
Start Date
January 31, 2007
Primary Completion Date
August 31, 2008
Study Completion Date
August 31, 2008
TPI 287
160 mg/m2 every three weeks for six cycles
TPI 287
160 mg/m2 intravenously over 60 minutes every three weeks until toxicity or progression of disease.
Tennessee Oncology, PLLC, Nashville
University of Kentucky, Lexington
Kansas City Cancer Center South, Kansas City
Cedars-Sinai Medical Center, Los Angeles
Comprehensive Cancer Center at Desert Mountain, Palm Springs
St. Barnabas Medical Center, Livingston
Lead Sponsor
Cortice Biosciences, Inc.
INDUSTRY